News

The TGA has approved donanemab for Alzheimer’s disease. How does this drug work and who will be able to access it?
Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.
Eli Lilly and Company (LLY) Gains Approval in Australia for Early Alzheimer’s Treatment
Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved ...
Eli Lilly’s Alzheimer’s drug cleared in Australia despite setback for Biogen
Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...
Eli Lilly's Alzheimer's Drug Gets Approval in Australia
Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration granted marketing ...
FDA crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...
Fierce Pharma4d
As Eli Lilly outperforms Novo in market, it also replaces its rival in annual IDEA Innovation rankings
As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...
BioSpace5d
FDA Clears First Alzheimer’s Blood Test, Lending ‘Momentum’ to Lilly’s Kisunla, Biogen’s Leqembi
Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...